Compare Novo Nordisk A/S (NVO) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Paychex, Inc. — how do they compare? Novo Nordisk A/S trades at $46.51 (market cap $207.85B), while Paychex, Inc. trades at $120.4 (market cap $43.14B). The key difference: Novo Nordisk A/S is far larger — about 4.8× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (3.92%). Which is the better fit depends on your goals.
| NVO | PAYX | |
|---|---|---|
Market Cap | $207.85B | $43.14B |
Sector | Health | Industrials |
52-Week High | $63.98 | $140.81 |
52-Week Low | $35.29 | $85.57 |
Enterprise Value | $222.55B | $46.63B |
Dividend Yield | 3.81% | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Paychex (PAYX) trades at $119.93, down 1.03% today, with a bullish technical outlook and strong profitability. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.33. The company maintains robust margins, including a 27.03% net income margin, and pays a steady dividend of $1.19 quarterly. Cash flow trends indicate operational strength, though 2025 saw significant investing outflows.
The stock presents a mixed outlook: solid fundamentals and dividend appeal are offset by a consensus 'Hold' rating and a price target below the current level. Risks include high valuation multiples and potential economic sensitivity for small business clients. Upside depends on sustained earnings growth and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
